Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

Published:2004-07-01 Issue:13 Volume:10 Page:4383-4388
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Park Jinny,Park Byung Bae,Kim Jee Youn,Lee Se-Hoon,Lee Soon Il,Kim Ho Young,Kim Jung Han,Park Se Hoon,Lee Kyung-Eun,Park Joon Oh,Kim Kihyun,Jung Chul Won,Park Young Suk,Im Young-Hyuck,Kang Won Ki,Lee Mark H.,Park Keunchil

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches;International Journal of Environmental Research and Public Health;2022-11-02

2. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials;Tumor Biology;2014-11-23

3. Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma;Oncology Letters;2014-11-04

4. Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Males, Smokers, and Non-adenocarcinoma Lung Cancer in Patients with EGFR Mutations;The International Journal of Biological Markers;2013-07

5. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;PLoS ONE;2013-01-30